Sector News

Mylan offers $28 billion for Perrigo

April 9, 2015
Life sciences
Mylan has made an offer to buy Dublin, Ireland-based Perrigo for more than $28 billion, as the current acquisitions trend in pharma continues at pace.
 
The company said it would pay $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the latter’s stock price as of April 3, 2015.
 
According to Mylan, the marriage of these “highly complementary businesses” would create “a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile”. 
 
In a letter to Perrigo’s chairman, Mylan chief Robert Coury noted that the proposed transaction “makes compelling strategic sense” and would result in a combined company with “a very strong financial profile”, with annual sales of more than $15 billion.
 
Perrigo confirmed receipt of the offer, and noted that its board will now meet to discuss the proposal.
 
Mylan’s move comes just months after it relocated its headquarters from the US to The Netherlands as part of its purchase of Abbott’s main branded generics business, thereby considerably cutting its tax bill.
 
By Selina McKee
 
Source: Pharma Times
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.